Advertisement

Picture Kentro Design Corporate and Web Design for Start Ups 2x 650x80px
Organisation › Details

iOmx Therapeutics AG

iOmx Therapeutics (www.iomx.com) is a biopharmaceutical company focused on developing first-in-class cancer immunotherapies addressing novel immune checkpoints hijacked by cancer cells. Utilizing its iOTarg™ high-throughput screening platform, iOmx has identified a number of proprietary tumor-associated next-generation immune checkpoints and is advancing a preclinical stage pipeline of promising drug candidates that have the potential to address cancers that are resistant to current immunotherapies. The company’s lead program IMT-07 targets SIK3, an immune protective kinase in multiple solid tumors; the IMT-18 program is a first-in-class antibody designed to inhibit IGSF11, an immune checkpoint in PD-1/PD-L1-resistant tumors. Founded in 2016 based on the work of its scientific founders Philipp Beckhove, MD, and Nisit Khandelwal, Ph.D., conducted at the German Cancer Research Center, iOmx is backed by international venture capital investors, such as Wellington Partners, Sofinnova Partners and M Ventures as well as MIG Capital and Athos Service. iOmx is based in Martinsried/Munich, Germany. *

 

Period Start 2016-06-08 renamed
  Predecessor Immodutome AG
Products Industry cancer drug
  Industry 2 drug development
Persons Person Papadimitriou, Apollon (iOmx Therapeutics 201910– CEO joined 2017 as CDO before Roche)
  Person 2 Irsfeld, Marcus (iOmx Therapeutics 201910– CFO before ProCorde GmbH + Averitas Pharma Inc)
     
Region Region Martinsried
  Country Germany
  Street 13 Fraunhoferstr.
  City 82152 Martinsried
  Tel +49-89-8999-7090-0
    Address record changed: 2021-10-07
     
Basic data Employees B: 11 to 50 (2018-12-20)
     
    * Document for �About Section�: iOmx Therapeutics AG. (10/5/21). "Press Release: iOmx Therapeutics Raises EUR 65 Million in Series B Round". Martinsried.
     
   
Record changed: 2022-03-17

Advertisement

Picture [iito] Fighting Customers 650x100px

More documents for iOmx Therapeutics AG


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top